eClinical Solutions Market - Global Forecast to 2029
| 出版社 | MarketsandMarkets |
| 出版年月 | 2024年7月 |
| ページ数 | 300 |
| 図表数 | 300 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global eClinical solutions market is projected to reach USD 22.1 billion by 2029 from USD 11.6 billion in 2024, at a high CAGR of 13.7% during the forecast period.
世界のeクリニカルソリューション市場は、予測期間中に13.7%という高いCAGRで、2024年の116億米ドルから2029年までに221億米ドルに達すると予測されています。
Growth Drivers include the rising operational costs and regulatory obligations for all clinical research studies, adoption of innovative software solutions for clinical research, favourable government funding received for clinical trials, rising need for better standardization and quality of clinical data, and growing R&D expenditure on drug development by pharmaceutical-biotech companies. There are some inhibitive factors, such as the high rate of implementation of eClinical solutions, scarcity of skilled professionals to implement and manage these solutions, and inadequate awareness about the benefits of eClinical solutions among researchers.
“In 2023, data collection segment constituted the largest segment in the eClinical solutions market, by application.”
In 2023, the data collection segment accounted for the biggest proportion of the eClinical solutions market, by application. This growth is primarily driven by solutions such as electronic data capture (EDC) systems, which streamline the process by reducing manual errors, speeding up data entry, and allowing for real-time access to data; the growing need to comply with stringent regulatory standards and support remote and decentralised trials; and its growing importance in clinical trial success, as it ensures the integrity and quality of the data being gathered.
“In 2023, the pharmaceutical & biopharmaceutical companies held the largest market share among end users.”
In 2023, pharmaceutical and biopharmaceutical firms accounted for the highest proportion of the eClinical solutions market by end user. This dominance stems primarily from the enormous number of corporations’ investments in clinical trials and drug development. These companies run numerous clinical studies to get their innovative medications and cures to market, necessitating significantly improved eClinical systems to manage the complicated processes involved. Furthermore, these organizations have significant financial resources to invest in eClinical solutions, allowing them to adopt cutting-edge technology and developments, hence, fueling the industry.
“In 2023, North America was the largest regional market for eClinical solutions market.”
In 2023, North America had the highest share of the eClinical Solutions market. This segment’s highest share is attributed to its advanced healthcare infrastructure, major R&D investments, and strict regulatory environment. Big Pharma companies like Pfizer and Johnson & Johnson that conduct clinical trials on a large scale are the ones responsible for the high demand of these solutions. The region’s high digital literacy and technological innovation given by companies such as Medidata Solutions propel the widespread use of eClinical solutions. The availability of regulatory frameworks, such as the FDA’s 21 CFR Part 11, ensures compliance while driving up demand for sophisticated data management and clinical trial solutions.
The break-down of primary participants is as mentioned below:
- By Company Type – Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
- By Designation – C-level: 42%, Director-level: 31%, and Others: 27%
- By Region – North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, Latin America: 5%
Key Players in the eClinical Solutions Market
The key players functioning in the EClinical solutions market include Medidata (A Dassault Systèmes Company) (France), Veeva Systems (US), IQVIA Inc. (US), ICON plc (Ireland), Oracle (US), Signant Health (US), Clario (US), and eClinical Solutions (US).
Research Coverage:
The report analyses the eClinical solutions market. It aims to estimate the market size and future growth potential of various market segments based on product, deployment model, application, clinical trial phase, end-user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms and new entrants/smaller firms to gauge the market’s pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
Analysis of key drivers: (increasing operational costs and regulatory requirements associated with clinical research studies), restraints (high implementation costs associated with eClinical solutions), opportunities (growing number of clinical trials in developing nations), and challenges (concerns pertaining to patient privacy) influencing the growth of the eClinical solutions market.
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the eClinical solutions market.
Market Development: Comprehensive information on the lucrative emerging markets, products, deployment models, applications, clinical trial phase, end-users, and regions.
Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the eClinical solutions market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the eClinical solutions market like Medidata (A Dassault Systèmes Company) (France), Veeva Systems (US), IQVIA Inc. (US), ICON plc (Ireland), Oracle (US), Signant Health (US), Clario (US), and eClinical Solutions (US).
Table of Contents
1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS AND EXCLUSIONS 29
1.3 MARKET SCOPE 30
1.3.1 MARKETS COVERED 30
1.3.2 YEARS CONSIDERED 31
1.3.3 CURRENCY CONSIDERED 31
1.4 STAKEHOLDERS 31
1.5 SUMMARY OF CHANGES 32
1.5.1 IMPACT OF AI/GEN AI 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.1.1 SECONDARY DATA 34
2.1.1.1 Key data from secondary sources 35
2.1.2 PRIMARY DATA 35
2.1.2.1 Key data from primary sources 37
2.1.2.2 Insights from primary experts 38
2.2 MARKET SIZE ESTIMATION 39
2.3 DATA TRIANGULATION 43
2.4 MARKET SHARE ESTIMATION 43
2.5 RESEARCH ASSUMPTIONS 44
2.6 RESEARCH LIMITATIONS 44
2.6.1 METHODOLOGY-RELATED LIMITATIONS 44
2.6.2 SCOPE-RELATED LIMITATIONS 44
2.7 RISK ASSESSMENT 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 51
4.1 ECLINICAL SOLUTIONS MARKET OVERVIEW 51
4.2 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE
AND COUNTRY, 2024 52
4.3 ECLINICAL SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
4.4 ECLINICAL SOLUTIONS MARKET REGIONAL MIX 53
4.5 ECLINICAL SOLUTIONS MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
5.2.1 DRIVERS 56
5.2.1.1 Growing focus on cost-effective processes 56
5.2.1.2 Favorable government support and funding 57
5.2.1.3 Need for data standardization 57
5.2.1.4 Increasing R&D expenditure on drug development 58
5.2.2 RESTRAINTS 58
5.2.2.1 High implementation costs 58
5.2.2.2 Lack of skilled professionals 58
5.2.2.3 Limited awareness among researchers 58
5.2.3 OPPORTUNITIES 59
5.2.3.1 Increasing number of clinical trials 59
5.2.3.2 Outsourcing of clinical trials 59
5.2.3.3 Gradual shift toward real-time data analysis 59
5.2.4 CHALLENGES 60
5.2.4.1 Limited adoption in developing and underdeveloped countries 60
5.2.4.2 Software reliability issues 60
5.2.4.3 Patient privacy concerns 60
5.3 ECOSYSTEM ANALYSIS 61
5.3.1 HEALTHCARE PROVIDERS 61
5.3.2 CLOUD PROVIDERS 61
5.3.3 GOVERNMENT AGENCIES AND REGULATORY BODIES 61
5.3.4 ECLINICAL SOLUTION COMPANIES 61
5.4 CASE STUDY ANALYSIS 63
5.4.1 ENHANCED PATIENT RECORDS USING MEDIDATA ECOA APP 63
5.4.2 IMPROVED ALZHEIMER’S TREATMENT WITH LEQEMB THERAPY 64
5.4.3 EFFICIENT CLINICAL TRIAL UTILIZING SCALE MANAGEMENT EXPERTISE 65
5.5 VALUE CHAIN ANALYSIS 66
5.6 PORTER’S FIVE FORCES ANALYSIS 68
5.6.1 BARGAINING POWER OF SUPPLIERS 69
5.6.2 BARGAINING POWER OF BUYERS 69
5.6.3 THREAT OF SUBSTITUTES 69
5.6.4 THREAT OF NEW ENTRANTS 69
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 69
5.7 REGULATORY LANDSCAPE 70
5.7.1 REGULATORY ANALYSIS 70
5.7.1.1 North America 70
5.7.1.2 Europe 71
5.7.1.3 Asia Pacific 72
5.7.1.4 Latin America 73
5.7.1.5 Middle East & Africa 73
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
5.8 PATENT ANALYSIS 76
5.8.1 PATENT PUBLICATION TRENDS FOR ECLINICAL SOLUTIONS 76
5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS 77
5.9 TECHNOLOGY ANALYSIS 79
5.9.1 KEY TECHNOLOGIES 79
5.9.1.1 AI-enabled and integrated platforms 79
5.9.1.2 Clinical data integration 79
5.9.2 COMPLEMENTARY TECHNOLOGIES 80
5.9.2.1 Cloud computing 80
5.9.2.2 Analytical tools 80
5.9.3 ADJACENT TECHNOLOGIES 80
5.9.3.1 Electronic health records 80
5.9.3.2 Real-world data 80
5.9.3.3 Bioinformatics 81
5.10 INDUSTRY TRENDS 81
5.10.1 DECENTRALIZED CLINICAL TRIALS 81
5.10.2 TELEMEDICINE 81
5.10.3 BIG DATA 81
5.11 PRICING ANALYSIS 82
5.11.1 INDICATIVE PRICING ANALYSIS, BY DEPLOYMENT MODEL 83
5.11.2 AVERAGE SELLING PRICE TREND, BY REGION 85
5.12 KEY CONFERENCES AND EVENTS, 2024–2025 86
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 87
5.13.1 BUYING CRITERIA 88
5.14 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 89
5.15 END-USER ANALYSIS 90
5.15.1 UNMET NEEDS 90
5.15.2 END-USER EXPECTATIONS 91
5.16 INVESTMENT AND FUNDING SCENARIO 92
5.17 IMPACT OF AI/GEN AI ON ECLINICAL SOLUTIONS MARKET 93
5.17.1 KEY USE CASES 94
5.17.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 94
5.17.2.1 Case study 94
5.17.2.2 Clinical trial management system market 95
5.17.2.3 Clinical trial market 95
5.17.2.4 Electronic clinical outcome assessment solution market 96
5.17.3 USER READINESS AND IMPACT ASSESSMENT 96
5.17.3.1 User readiness 96
5.17.3.1.1 Pharmaceutical and biopharmaceutical companies 96
5.17.3.1.2 Contract research organizations 96
5.17.3.2 Impact assessment 97
5.17.3.2.1 User A: Pharmaceutical & biopharmaceutical companies 97
5.17.3.2.1.1 Implementation 97
5.17.3.2.1.2 Impact 97
5.17.3.2.2 User B: Academic research institutes 97
5.17.3.2.2.1 Implementation 97
5.17.3.2.2.2 Impact 97
6 ECLINICAL SOLUTIONS MARKET, BY PRODUCT 98
6.1 INTRODUCTION 99
6.2 ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SOLUTIONS 100
6.2.1 RISING NEED TO REDUCE TIME AND COSTS IN CLINICAL TRIALS TO ENCOURAGE GROWTH 100
6.3 CLINICAL TRIAL MANAGEMENT SOLUTIONS 101
6.3.1 RISING DEMAND FOR SITE & DATA COLLECTION SOLUTIONS TO FACILITATE GROWTH 101
6.4 CLINICAL ANALYTICS PLATFORMS 102
6.4.1 GROWING ADOPTION OF ELECTRONIC MEDICAL RECORDS TO BOOST MARKET 102
6.5 RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SOLUTIONS 104
6.5.1 GROWING TREND OF GLOBALIZATION TO FUEL MARKET 104
6.6 ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS 105
6.6.1 INCREASING ADOPTION OF EDIARIES TO AID GROWTH 105
6.7 ELECTRONIC TRIAL MASTER FILE SOLUTIONS 106
6.7.1 IMPROVED INFORMATION SEARCH AND RETRIEVAL TO FUEL MARKET 106
6.8 ELECTRONIC CONSENT SOLUTIONS 107
6.8.1 GROWING INCLINATION TOWARD DIGITIZATION TO PROMOTE GROWTH 107
6.9 REGULATORY INFORMATION MANAGEMENT SOLUTIONS 108
6.9.1 ENHANCED REGULATORY SUBMISSION PROCESS TO AUGMENT GROWTH 108
6.10 CLINICAL DATA INTEGRATION PLATFORMS 109
6.10.1 GROWING VOLUME OF CLINICAL DATA AND IMPROVED CLOUD TECHNOLOGY TO PROPEL MARKET 109
6.11 SAFETY SOLUTIONS 110
6.11.1 GROWING ADOPTION OF ECLINICAL SOFTWARE TO SUPPORT MARKET GROWTH 110
6.12 OTHER SOLUTIONS 111
7 ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL 113
7.1 INTRODUCTION 114
7.2 WEB-HOSTED & CLOUD-BASED MODELS 114
7.2.1 GROWING DEMAND FOR CLOUD-BASED SOLUTIONS TO AUGMENT GROWTH 114
7.3 ON-PREMISE MODELS 116
7.3.1 MINIMIZED DATA BREACHES AND EXTERNAL ATTACK RISKS TO SUPPORT MARKET 116
8 ECLINICAL SOLUTIONS MARKET, BY APPLICATION 117
8.1 INTRODUCTION 118
8.2 DATA COLLECTION 119
8.2.1 IMPROVED TRIAL EFFICIENCY TO DRIVE MARKET 119
8.3 DOCUMENT MANAGEMENT & STORAGE 120
8.3.1 RISING INCLINATION TOWARD STREAMLINED DOCUMENT WORKFLOWS TO FUEL MARKET 120
8.4 SUPPLY MANAGEMENT 121
8.4.1 NEED TO ADDRESS COMPLEXITIES IN MANAGING CLINICAL TRIAL SUPPLIES TO BOOST MARKET 121
8.5 DATA ANALYTICS 122
8.5.1 INCREASING NEED FOR OPTIMIZED TRIAL DESIGNS TO AID GROWTH 122
8.6 CLINICAL TRIAL OPERATIONS 123
8.6.1 GROWING FOCUS ON ENHANCED DRUG DEVELOPMENT TO PROPEL MARKET 123
8.7 REGULATORY INFORMATION MANAGEMENT 124
8.7.1 EVOLVING GLOBAL REGULATORY STANDARDS TO STIMULATE GROWTH 124
8.8 OTHER APPLICATIONS 125
9 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE 127
9.1 INTRODUCTION 128
9.2 PHASE I 128
9.2.1 INCREASING DEMAND FOR ACCURATE CLINICAL DATA MANAGEMENT TO ACCELERATE GROWTH 128
9.3 PHASE II 129
9.3.1 PUSH TOWARD FASTER DRUG DEVELOPMENT TO FACILITATE GROWTH 129
9.4 PHASE III 131
9.4.1 INVOLVEMENT OF LARGE PATIENT POPULATION TO ENCOURAGE SEGMENT GROWTH 131
9.5 PHASE IV 133
9.5.1 GROWING EMPHASIS ON SAFE DRUGS TO DRIVE MARKET 133
10 ECLINICAL SOLUTIONS MARKET, BY END USER 134
10.1 INTRODUCTION 135
10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 135
10.2.1 INCREASING R&D EXPENDITURE TO DRIVE MARKET 135
10.3 CONTRACT RESEARCH ORGANIZATIONS 137
10.3.1 GROWING OUTSOURCING OF CLINICAL TRIALS TO FUEL MARKET 137
10.4 CONSULTING SERVICE COMPANIES 138
10.4.1 INCREASING COMPLEXITIES AND COSTS OF CLINICAL DATA MANAGEMENT TO PROPEL MARKET 138
10.5 MEDICAL DEVICE MANUFACTURERS 139
10.5.1 RISING DEVELOPMENT OF NEW MEDICAL DEVICES TO BOOST MARKET 139
10.6 HOSPITALS & HEALTHCARE PROVIDERS 140
10.6.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND ECLINICAL SOLUTION PROVIDERS TO STIMULATE MARKET 140
10.7 ACADEMIC & RESEARCH INSTITUTES 141
10.7.1 FAVORABLE GOVERNMENT SUPPORT FOR CLINICAL RESEARCH TO EXPEDITE GROWTH 141
10.8 GOVERNMENT ORGANIZATIONS 142
10.8.1 INCREASED ADOPTION BY HEALTH DEPARTMENTS AND REGULATORY BODIES TO SPEED UP GROWTH 142
10.9 OTHER END USERS 143
11 ECLINICAL SOLUTIONS MARKET, BY REGION 145
11.1 INTRODUCTION 146
11.2 NORTH AMERICA 146
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 150
11.2.2 US 151
11.2.2.1 Rising government funding for pharmaceutical R&D to drive market 151
11.2.3 CANADA 154
11.2.3.1 Advanced facilities and shorter approval times for drug candidates to fuel market 154
11.3 EUROPE 158
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 161
11.3.2 GERMANY 162
11.3.2.1 High number of sponsored clinical trials to augment growth 162
11.3.3 UK 165
11.3.3.1 Increased investments by pharmaceutical companies to boost market 165
11.3.4 FRANCE 168
11.3.4.1 Booming generics market to aid growth 168
11.3.5 ITALY 171
11.3.5.1 Favorable drug approval scenario to support market growth 171
11.3.6 SPAIN 174
11.3.6.1 Robust network of research centers, universities, and hospitals to encourage growth 174
11.3.7 REST OF EUROPE 177
11.4 ASIA PACIFIC 180
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 184
11.4.2 CHINA 185
11.4.2.1 Low manufacturing costs and huge demand for medicines to expedite growth 185
11.4.3 INDIA 188
11.4.3.1 Growing foreign direct investments to facilitate market growth 188
11.4.4 JAPAN 191
11.4.4.1 Drug discovery and development initiatives to promote growth 191
11.4.5 REST OF ASIA PACIFIC 194
11.5 LATIN AMERICA 197
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 200
11.5.2 BRAZIL 201
11.5.2.1 Higher adoption of advanced digital technologies to stimulate growth 201
11.5.3 MEXICO 203
11.5.3.1 Government initiatives to enhance digital infrastructure of healthcare to propel market 203
11.5.4 REST OF LATIN AMERICA 206
11.6 MIDDLE EAST & AFRICA 209
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 212
11.6.2 GCC COUNTRIES 213
11.6.2.1 Growing modernization initiatives in healthcare sector to support market growth 213
11.6.3 REST OF MIDDLE EAST & AFRICA 216
12 COMPETITIVE LANDSCAPE 220
12.1 INTRODUCTION 220
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN 220
12.3 REVENUE ANALYSIS, 2019–2023 222
12.4 MARKET SHARE ANALYSIS, 2023 223
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 226
12.5.1 STARS 226
12.5.2 EMERGING LEADERS 226
12.5.3 PERVASIVE PLAYERS 226
12.5.4 PARTICIPANTS 226
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 228
12.5.5.1 Company footprint 228
12.5.5.2 Product footprint 229
12.5.5.3 Application footprint 230
12.5.5.4 End-user footprint 231
12.5.5.5 Region footprint 232
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 233
12.6.1 PROGRESSIVE COMPANIES 233
12.6.2 RESPONSIVE COMPANIES 233
12.6.3 DYNAMIC COMPANIES 233
12.6.4 STARTING BLOCKS 233
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 235
12.7 COMPANY EVALUATION AND FINANCIAL METRICS 237
12.8 BRAND/PRODUCT COMPARISON 238
12.9 COMPETITIVE SCENARIO 239
12.9.1 PRODUCT LAUNCHES AND ENHANCEMENTS 239
12.9.2 DEALS 240
12.9.3 EXPANSIONS 241
12.9.4 OTHER DEVELOPMENTS 241
13 COMPANY PROFILES 242
13.1 KEY PLAYERS 242
13.1.1 MEDIDATA (A DASSAULT SYSTÈMES COMPANY) 242
13.1.1.1 Business overview 242
13.1.1.2 Products offered 243
13.1.1.3 Recent developments 244
13.1.1.3.1 Product launches and enhancements 244
13.1.1.3.2 Deals 245
13.1.1.4 MnM view 246
13.1.1.4.1 Right to win 246
13.1.1.4.2 Strategic choices 246
13.1.1.4.3 Weaknesses and competitive threats 246
13.1.2 VEEVA SYSTEMS 247
13.1.2.1 Business overview 247
13.1.2.2 Products offered 248
13.1.2.3 Recent developments 248
13.1.2.3.1 Product launches and enhancements 248
13.1.2.3.2 Deals 249
13.1.2.4 MnM view 250
13.1.2.4.1 Right to win 250
13.1.2.4.2 Strategic choices 250
13.1.2.4.3 Weaknesses and competitive threats 250
13.1.3 IQVIA INC. 251
13.1.3.1 Business overview 251
13.1.3.2 Products offered 252
13.1.3.3 Recent developments 253
13.1.3.3.1 Deals 253
13.1.3.4 MnM view 254
13.1.3.4.1 Right to win 254
13.1.3.4.2 Strategic choices 254
13.1.3.4.3 Weaknesses and competitive threats 254
13.1.4 ICON PLC 255
13.1.4.1 Business overview 255
13.1.4.2 Products offered 256
13.1.4.3 Recent developments 256
13.1.4.3.1 Product launches and enhancements 256
13.1.4.3.2 Deals 256
13.1.5 ORACLE 257
13.1.5.1 Business overview 257
13.1.5.2 Products offered 258
13.1.5.3 Recent developments 259
13.1.5.3.1 Deals 259
13.1.6 SIGNANT HEALTH 260
13.1.6.1 Business overview 260
13.1.6.2 Products offered 260
13.1.6.3 Recent developments 261
13.1.6.3.1 Product launches and enhancements 261
13.1.6.3.2 Deals 261
13.1.7 CLARIO 262
13.1.7.1 Business overview 262
13.1.7.2 Products offered 262
13.1.7.3 Recent developments 262
13.1.7.3.1 Product launches and enhancements 262
13.1.7.3.2 Deals 263
13.1.7.3.3 Other developments 263
13.1.8 ECLINICAL SOLUTIONS 264
13.1.8.1 Business overview 264
13.1.8.2 Products offered 264
13.1.8.3 Recent developments 265
13.1.8.3.1 Product launches and enhancements 265
13.1.8.3.2 Deals 265
13.1.9 CLINION 266
13.1.9.1 Business overview 266
13.1.9.2 Products offered 266
13.1.9.3 Recent developments 266
13.1.9.3.1 Product launches and enhancements 266
13.1.9.3.2 Deals 267
13.1.10 MAXISIT 268
13.1.10.1 Business overview 268
13.1.10.2 Products offered 268
13.1.11 4G CLINICAL 270
13.1.11.1 Business overview 270
13.1.11.2 Products offered 270
13.1.11.3 Recent developments 271
13.1.11.3.1 Deals 271
13.1.12 FOUNTAYN 272
13.1.12.1 Business overview 272
13.1.12.2 Products offered 272
13.1.13 SAAMA 273
13.1.13.1 Business overview 273
13.1.13.2 Products offered 273
13.1.13.3 Recent developments 274
13.1.13.3.1 Deals 274
13.1.14 MEDNET 275
13.1.14.1 Business overview 275
13.1.14.2 Products offered 275
13.1.14.3 Recent developments 276
13.1.14.3.1 Product launches and enhancements 276
13.1.14.3.2 Deals 276
13.1.15 ADVARRA 277
13.1.15.1 Business overview 277
13.1.15.2 Products offered 277
13.1.15.3 Recent developments 278
13.1.15.3.1 Product launches and enhancements 278
13.1.15.3.2 Deals 278
13.1.16 CAIDYA 279
13.1.16.1 Business overview 279
13.1.16.2 Products offered 279
13.1.16.3 Recent developments 280
13.1.16.3.1 Deals 280
13.1.16.3.2 Expansions 280
13.1.17 OPENCLINICA, LLC 281
13.1.17.1 Business overview 281
13.1.17.2 Products offered 281
13.1.17.3 Recent developments 282
13.1.17.3.1 Deals 282
13.1.18 EVIDENTIQ 283
13.1.18.1 Business overview 283
13.1.18.2 Products offered 283
13.1.18.3 Recent developments 284
13.1.18.3.1 Product launches and enhancements 284
13.1.18.3.2 Deals 284
13.2 OTHER PLAYERS 285
13.2.1 RESEARCH MANAGER 285
13.2.2 ANJU SOFTWARE INC. 286
13.2.3 MEDRIO 287
13.2.4 CASTOR 288
13.2.5 REALTIME SOFTWARE SOLUTIONS, LLC 289
13.2.6 YPRIME, LLC. 290
13.2.7 VIAL 290
14 APPENDIX 291
14.1 DISCUSSION GUIDE 291
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 296
14.3 CUSTOMIZATION OPTIONS 298
14.4 RELATED REPORTS 298
14.5 AUTHOR DETAILS 299
LIST OF TABLES
TABLE 1 INCLUSIONS AND EXCLUSIONS 29
TABLE 2 ECLINICAL SOLUTIONS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 62
TABLE 3 ECLINICAL SOLUTIONS MARKET: PORTER’S FIVE FORCES 68
TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 73
TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 74
TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 74
TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 75
TABLE 8 INNOVATIONS AND PATENT REGISTRATIONS, 2022–2023 78
TABLE 9 INDICATIVE PRICING ANALYSIS OF ECLINICAL SOLUTIONS,
BY DEPLOYMENT MODEL 84
TABLE 10 ECLINICAL SOLUTIONS MARKET: KEY CONFERENCES AND EVENTS, 2024–2025 86
TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TOP 3 END USERS (%) 87
TABLE 12 KEY BUYING CRITERIA FOR TOP 3 END USERS 88
TABLE 13 UNMET NEEDS IN ECLINICAL SOLUTIONS MARKET 90
TABLE 14 END-USER EXPECTATIONS IN ECLINICAL SOLUTIONS MARKET 91
TABLE 15 ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 99
TABLE 16 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SOLUTIONS, BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 17 ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SOLUTIONS, BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 18 ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS,
BY COUNTRY, 2022–2029 (USD MILLION) 103
TABLE 19 ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SOLUTIONS, BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 20 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 21 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SOLUTIONS, BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 22 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 23 ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SOLUTIONS, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 24 ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS,
BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 25 ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY,
2022–2029 (USD MILLION) 111
TABLE 26 ECLINICAL SOLUTIONS MARKET FOR OTHER SOLUTIONS, BY COUNTRY,
2022–2029 (USD MILLION) 112
TABLE 27 ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 114
TABLE 28 ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED & CLOUD-BASED MODELS,
BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 29 ECLINICAL SOLUTIONS MARKET FOR ON-PREMISE MODELS, BY COUNTRY,
2022–2029 (USD MILLION) 116
TABLE 30 ECLINICAL SOLUTIONS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 118
TABLE 31 ECLINICAL SOLUTIONS MARKET FOR DATA COLLECTION, BY COUNTRY,
2022–2029 (USD MILLION) 119
TABLE 32 ECLINICAL SOLUTIONS MARKET FOR DOCUMENT MANAGEMENT & STORAGE,
BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 33 ECLINICAL SOLUTIONS MARKET FOR SUPPLY MANAGEMENT, BY COUNTRY,
2022–2029 (USD MILLION) 121
TABLE 34 ECLINICAL SOLUTIONS MARKET FOR DATA ANALYTICS, BY COUNTRY,
2022–2029 (USD MILLION) 122
TABLE 35 ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL OPERATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 36 ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT, BY COUNTRY, 2022–2029 (USD MILLION) 125
TABLE 37 ECLINICAL SOLUTIONS MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2022–2029 (USD MILLION) 126
TABLE 38 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,
2022–2029 (USD MILLION) 128
TABLE 39 ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY,
2022–2029 (USD MILLION) 129
TABLE 40 ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY,
2022–2029 (USD MILLION) 130
TABLE 41 ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY,
2022–2029 (USD MILLION) 132
TABLE 42 ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY,
2022–2029 (USD MILLION) 133
TABLE 43 ECLINICAL SOLUTIONS MARKET, BY END USER, 2022–2029 (USD MILLION) 135
TABLE 44 ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 45 ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 46 ECLINICAL SOLUTIONS MARKET FOR CONSULTING SERVICE COMPANIES,
BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 47 ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS,
BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 48 ECLINICAL SOLUTIONS MARKET FOR HOSPITALS & HEALTHCARE PROVIDERS,
BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 49 ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 50 ECLINICAL SOLUTIONS MARKET FOR GOVERNMENT ORGANIZATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 51 ECLINICAL SOLUTIONS MARKET FOR OTHER END USERS, BY COUNTRY,
2022–2029 (USD MILLION) 144
TABLE 52 ECLINICAL SOLUTIONS MARKET, BY REGION, 2022–2029 (USD MILLION) 146
TABLE 53 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 148
TABLE 54 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 148
TABLE 55 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION) 149
TABLE 56 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 149
TABLE 57 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2022–2029 (USD MILLION) 149
TABLE 58 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY END USER,
2022–2029 (USD MILLION) 150
TABLE 59 US: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 152
TABLE 60 US: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 152
TABLE 61 US: ECLINICAL SOLUTIONS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 153
TABLE 62 US: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,
2022–2029 (USD MILLION) 153
TABLE 63 US: ECLINICAL SOLUTIONS MARKET, BY END USER, 2022–2029 (USD MILLION) 154
TABLE 64 CANADA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 155
TABLE 65 CANADA: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 155
TABLE 66 CANADA: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 156
TABLE 67 CANADA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,
2022–2029 (USD MILLION) 156
TABLE 68 CANADA: ECLINICAL SOLUTIONS MARKET, BY END USER,
2022–2029 (USD MILLION) 157
TABLE 69 EUROPE: ECLINICAL SOLUTIONS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 158
TABLE 70 EUROPE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 159
TABLE 71 EUROPE: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 159
TABLE 72 EUROPE: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 160
TABLE 73 EUROPE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,
2022–2029 (USD MILLION) 160
TABLE 74 EUROPE: ECLINICAL SOLUTIONS MARKET, BY END USER,
2022–2029 (USD MILLION) 161
TABLE 75 GERMANY: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 163
TABLE 76 GERMANY: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 163
TABLE 77 GERMANY: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 164
TABLE 78 GERMANY: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,
2022–2029 (USD MILLION) 164
TABLE 79 GERMANY: ECLINICAL SOLUTIONS MARKET, BY END USER,
2022–2029 (USD MILLION) 165
TABLE 80 UK: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 166
TABLE 81 UK: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 166
TABLE 82 UK: ECLINICAL SOLUTIONS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 167
TABLE 83 UK: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,
2022–2029 (USD MILLION) 167
TABLE 84 UK: ECLINICAL SOLUTIONS MARKET, BY END USER, 2022–2029 (USD MILLION) 168
TABLE 85 FRANCE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 169
TABLE 86 FRANCE: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 169
TABLE 87 FRANCE: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 170
TABLE 88 FRANCE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,
2022–2029 (USD MILLION) 170
TABLE 89 FRANCE: ECLINICAL SOLUTIONS MARKET, BY END USER,
2022–2029 (USD MILLION) 171
TABLE 90 ITALY: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 172
TABLE 91 ITALY: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 172
TABLE 92 ITALY: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 173
TABLE 93 ITALY: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,
2022–2029 (USD MILLION) 173
TABLE 94 ITALY: ECLINICAL SOLUTIONS MARKET, BY END USER, 2022–2029 (USD MILLION) 174
TABLE 95 SPAIN: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 175
TABLE 96 SPAIN: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 175
TABLE 97 SPAIN: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 176
TABLE 98 SPAIN: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,
2022–2029 (USD MILLION) 176
TABLE 99 SPAIN: ECLINICAL SOLUTIONS MARKET, BY END USER, 2022–2029 (USD MILLION) 177
TABLE 100 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 178
TABLE 101 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION) 178
TABLE 102 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 179
TABLE 103 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2022–2029 (USD MILLION) 179
TABLE 104 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY END USER,
2022–2029 (USD MILLION) 180
TABLE 105 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 182
TABLE 106 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 182
TABLE 107 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 183
TABLE 108 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 183
TABLE 109 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,
2022–2029 (USD MILLION) 183
TABLE 110 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY END USER,
2022–2029 (USD MILLION) 184
TABLE 111 CHINA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 186
TABLE 112 CHINA: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 186
TABLE 113 CHINA: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 187
TABLE 114 CHINA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,
2022–2029 (USD MILLION) 187
TABLE 115 CHINA: ECLINICAL SOLUTIONS MARKET, BY END USER,
2022–2029 (USD MILLION) 188
TABLE 116 INDIA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 189
TABLE 117 INDIA: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 189
TABLE 118 INDIA: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 190
TABLE 119 INDIA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,
2022–2029 (USD MILLION) 190
TABLE 120 INDIA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2022–2029 (USD MILLION) 191
TABLE 121 JAPAN: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 192
TABLE 122 JAPAN: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 192
TABLE 123 JAPAN: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 193
TABLE 124 JAPAN: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,
2022–2029 (USD MILLION) 193
TABLE 125 JAPAN: ECLINICAL SOLUTIONS MARKET, BY END USER,
2022–2029 (USD MILLION) 194
TABLE 126 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 195
TABLE 127 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION) 195
TABLE 128 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 196
TABLE 129 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2022–2029 (USD MILLION) 196
TABLE 130 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY END USER,
2022–2029 (USD MILLION) 197
TABLE 131 LATIN AMERICA: ECLINICAL SOLUTIONS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 198
TABLE 132 LATIN AMERICA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 198
TABLE 133 LATIN AMERICA: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 199
TABLE 134 LATIN AMERICA: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 199
TABLE 135 LATIN AMERICA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2022–2029 (USD MILLION) 199
TABLE 136 LATIN AMERICA: ECLINICAL SOLUTIONS MARKET, BY END USER,
2022–2029 (USD MILLION) 200
TABLE 137 BRAZIL: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 201
TABLE 138 BRAZIL: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 202
TABLE 139 BRAZIL: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 202
TABLE 140 BRAZIL: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,
2022–2029 (USD MILLION) 202
TABLE 141 BRAZIL: ECLINICAL SOLUTIONS MARKET, BY END USER,
2022–2029 (USD MILLION) 203
TABLE 142 MEXICO: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 204
TABLE 143 MEXICO: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 204
TABLE 144 MEXICO: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 205
TABLE 145 MEXICO: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,
2022–2029 (USD MILLION) 205
TABLE 146 MEXICO: ECLINICAL SOLUTIONS MARKET, BY END USER,
2022–2029 (USD MILLION) 206
TABLE 147 REST OF LATIN AMERICA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 207
TABLE 148 REST OF LATIN AMERICA: ECLINICAL SOLUTIONS MARKET,
BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION) 207
TABLE 149 REST OF LATIN AMERICA: ECLINICAL SOLUTIONS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 208
TABLE 150 REST OF LATIN AMERICA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2022–2029 (USD MILLION) 208
TABLE 151 REST OF LATIN AMERICA: ECLINICAL SOLUTIONS MARKET, BY END USER,
2022–2029 (USD MILLION) 209
TABLE 152 MIDDLE EAST & AFRICA: ECLINICAL SOLUTIONS MARKET, BY REGION,
2022–2029 (USD MILLION) 210
TABLE 153 MIDDLE EAST & AFRICA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 210
TABLE 154 MIDDLE EAST & AFRICA: ECLINICAL SOLUTIONS MARKET,
BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION) 211
TABLE 155 MIDDLE EAST & AFRICA: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 211
TABLE 156 MIDDLE EAST & AFRICA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2022–2029 (USD MILLION) 211
TABLE 157 MIDDLE EAST & AFRICA: ECLINICAL SOLUTIONS MARKET, BY END USER,
2022–2029 (USD MILLION) 212
TABLE 158 GCC COUNTRIES: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 214
TABLE 159 GCC COUNTRIES: ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION) 214
TABLE 160 GCC COUNTRIES: ECLINICAL SOLUTIONS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 215
TABLE 161 GCC COUNTRIES: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2022–2029 (USD MILLION) 215
TABLE 162 GCC COUNTRIES: ECLINICAL SOLUTIONS MARKET, BY END USER,
2022–2029 (USD MILLION) 216
TABLE 163 REST OF MIDDLE EAST & AFRICA: ECLINICAL SOLUTIONS MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 217
TABLE 164 REST OF MIDDLE EAST & AFRICA: ECLINICAL SOLUTIONS MARKET,
BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION) 217
TABLE 165 REST OF MIDDLE EAST & AFRICA: ECLINICAL SOLUTIONS MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 218
TABLE 166 REST OF MIDDLE EAST & AFRICA: ECLINICAL SOLUTIONS MARKET,
BY CLINICAL TRIAL PHASE, 2022–2029 (USD MILLION) 218
TABLE 167 REST OF MIDDLE EAST & AFRICA: ECLINICAL SOLUTIONS MARKET,
BY END USER, 2022–2029 (USD MILLION) 219
TABLE 168 ECLINICAL SOLUTIONS MARKET: DEGREE OF COMPETITION 223
TABLE 169 ECLINICAL SOLUTIONS MARKET: PRODUCT FOOTPRINT 229
TABLE 170 ECLINICAL SOLUTIONS MARKET: APPLICATION FOOTPRINT 230
TABLE 171 ECLINICAL SOLUTIONS MARKET: END-USER FOOTPRINT 231
TABLE 172 ECLINICAL SOLUTIONS MARKET: REGION FOOTPRINT 232
TABLE 173 ECLINICAL SOLUTIONS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 235
TABLE 174 ECLINICAL SOLUTIONS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 236
TABLE 175 ECLINICAL SOLUTIONS MARKET: PRODUCT LAUNCHES AND ENHANCEMENTS, JANUARY 2021–JUNE 2024 239
TABLE 176 ECLINICAL SOLUTIONS MARKET: DEALS, JANUARY 2021– JUNE 2024 240
TABLE 177 ECLINICAL SOLUTIONS MARKET: EXPANSIONS, JANUARY 2021– JUNE 2024 241
TABLE 178 ECLINICAL SOLUTIONS MARKET: OTHER DEVELOPMENTS,
JANUARY 2021– JUNE 2024 241
TABLE 179 MEDIDATA (A DASSAULT SYSTÈMES COMPANY): COMPANY OVERVIEW 242
TABLE 180 MEDIDATA (A DASSAULT SYSTÈMES COMPANY): PRODUCTS OFFERED 243
TABLE 181 MEDIDATA (A DASSAULT SYSTÈMES COMPANY): PRODUCT LAUNCHES AND ENHANCEMENTS, JANUARY 2021− JUNE 2024 244
TABLE 182 MEDIDATA (A DASSAULT SYSTÈMES COMPANY): DEALS,
JANUARY 2021− JUNE 2024 245
TABLE 183 VEEVA SYSTEMS: COMPANY OVERVIEW 247
TABLE 184 VEEVA SYSTEMS: PRODUCTS OFFERED 248
TABLE 185 VEEVA SYSTEMS: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2021− JUNE 2024 248
TABLE 186 VEEVA SYSTEMS: DEALS, JANUARY 2021− JUNE 2024 249
TABLE 187 IQVIA INC.: COMPANY OVERVIEW 251
TABLE 188 IQVIA INC.: PRODUCTS OFFERED 252
TABLE 189 IQVIA INC.: DEALS, JANUARY 2021−JUNE 2024 253
TABLE 190 ICON PLC: COMPANY OVERVIEW 255
TABLE 191 ICON PLC: PRODUCTS OFFERED 256
TABLE 192 ICON PLC: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2021− JUNE 2024 256
TABLE 193 ICON PLC: DEALS, JANUARY 2021− JUNE 2024 256
TABLE 194 ORACLE: COMPANY OVERVIEW 257
TABLE 195 ORACLE: PRODUCTS OFFERED 258
TABLE 196 ORACLE: DEALS, JANUARY 2021−JUNE 2024 259
TABLE 197 SIGNANT HEALTH: COMPANY OVERVIEW 260
TABLE 198 SIGNANT HEALTH: PRODUCTS OFFERED 260
TABLE 199 SIGNANT HEALTH: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2021− JUNE 2024 261
TABLE 200 SIGNANT HEALTH: DEALS, JANUARY 2021− JUNE 2024 261
TABLE 201 CLARIO: COMPANY OVERVIEW 262
TABLE 202 CLARIO: PRODUCTS OFFERED 262
TABLE 203 CLARIO: PRODUCT LAUNCHES AND ENHANCEMENTS, JANUARY 2021− JUNE 2024 262
TABLE 204 CLARIO: DEALS, JANUARY 2021− JUNE 2024 263
TABLE 205 CLARIO: OTHER DEVELOPMENTS, JANUARY 2021– JUNE 2024 263
TABLE 206 ECLINICAL SOLUTIONS: COMPANY OVERVIEW 264
TABLE 207 ECLINICAL SOLUTIONS: PRODUCTS OFFERED 264
TABLE 208 ECLINICAL SOLUTIONS: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2021− JUNE 2024 265
TABLE 209 ECLINICAL SOLUTIONS: DEALS, JANUARY 2021− JUNE 2024 265
TABLE 210 CLINION: COMPANY OVERVIEW 266
TABLE 211 CLINION: PRODUCTS OFFERED 266
TABLE 212 CLINION: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2021− JUNE 2024 266
TABLE 213 CLINION: DEALS, JANUARY 2021− JUNE 2024 267
TABLE 214 MAXISIT: COMPANY OVERVIEW 268
TABLE 215 MAXISIT: PRODUCTS OFFERED 268
TABLE 216 4G CLINICAL: COMPANY OVERVIEW 270
TABLE 217 4G CLINICAL: PRODUCTS OFFERED 270
TABLE 218 4G CLINICAL: DEALS, JANUARY 2021− JUNE 2024 271
TABLE 219 FOUNTAYN: COMPANY OVERVIEW 272
TABLE 220 FOUNTAYN: PRODUCTS OFFERED 272
TABLE 221 SAAMA: COMPANY OVERVIEW 273
TABLE 222 SAAMA: PRODUCTS OFFERED 273
TABLE 223 SAAMA: DEALS, JANUARY 2021− JUNE 2024 274
TABLE 224 MEDNET: COMPANY OVERVIEW 275
TABLE 225 MEDNET: PRODUCTS OFFERED 275
TABLE 226 MEDNET: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2021− JUNE 2024 276
TABLE 227 MEDNET: DEALS, JANUARY 2021− JUNE 2024 276
TABLE 228 ADVARRA: COMPANY OVERVIEW 277
TABLE 229 ADVARRA: PRODUCTS OFFERED 277
TABLE 230 ADVARRA: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2021− JUNE 2024 278
TABLE 231 ADVARRA: DEALS, JANUARY 2021− JUNE 2024 278
TABLE 232 CAIDYA: COMPANY OVERVIEW 279
TABLE 233 CAIDYA: PRODUCTS OFFERED 279
TABLE 234 CAIDYA: DEALS, JANUARY 2021− JUNE 2024 280
TABLE 235 CAIDYA: EXPANSIONS, JANUARY 2021− JUNE 2024 280
TABLE 236 OPENCLINICA, LLC: COMPANY OVERVIEW 281
TABLE 237 OPENCLINICA, LLC: PRODUCTS OFFERED 281
TABLE 238 OPENCLINICA, LLC: DEALS, JANUARY 2021− JUNE 2024 282
TABLE 239 EVIDENTIQ: COMPANY OVERVIEW 283
TABLE 240 EVIDENTIQ: PRODUCTS OFFERED 283
TABLE 241 EVIDENTIQ: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2021− JUNE 2024 284
TABLE 242 EVIDENTIQ: DEALS, JANUARY 2021− JUNE 2024 284
TABLE 243 RESEARCH MANAGER: COMPANY REVIEW 285
TABLE 244 ANJU SOFTWARE INC.: COMPANY REVIEW 286
TABLE 245 MEDRIO: COMPANY OVERVIEW 287
TABLE 246 CASTOR: COMPANY OVERVIEW 288
TABLE 247 REALTIME SOFTWARE SOLUTIONS, LLC: COMPANY OVERVIEW 289
TABLE 248 YPRIME, LLC.: COMPANY OVERVIEW 290
TABLE 249 VIAL: COMPANY OVERVIEW 290
LIST OF FIGURES
FIGURE 1 ECLINICAL SOLUTIONS MARKET SEGMENTATION 30
FIGURE 2 RESEARCH DESIGN 33
FIGURE 3 PRIMARY SOURCES 36
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 38
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 39
FIGURE 6 TOP-DOWN APPROACH 40
FIGURE 7 IMPACT ANALYSIS OF MARKET DYNAMICS, 2024–2029 41
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 42
FIGURE 9 DATA TRIANGULATION 43
FIGURE 10 ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION) 46
FIGURE 11 ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL,
2024 VS. 2029 (USD MILLION) 47
FIGURE 12 ECLINICAL SOLUTIONS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 48
FIGURE 13 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,
2024 VS. 2029 (USD MILLION) 49
FIGURE 14 ECLINICAL SOLUTIONS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 49
FIGURE 15 ECLINICAL SOLUTIONS MARKET, BY REGION, 2024–2029 (USD MILLION) 50
FIGURE 16 INCREASING ADOPTION OF ECLINICAL SOLUTIONS AND RISING R&D EXPENDITURE FOR DRUG DEVELOPMENT TO DRIVE MARKET 51
FIGURE 17 CHINA TO DOMINATE ASIA PACIFIC MARKET IN 2024 52
FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 53
FIGURE 19 NORTH AMERICA TO LEAD MARKET DURING FORECAST PERIOD 53
FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING
FORECAST PERIOD 54
FIGURE 21 ECLINICAL SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 55
FIGURE 22 ECLINICAL SOLUTIONS MARKET: ECOSYSTEM ANALYSIS 62
FIGURE 23 ECLINICAL SOLUTIONS MARKET: VALUE CHAIN ANALYSIS 66
FIGURE 24 PORTER’S FIVE FORCES ANALYSIS 68
FIGURE 25 PATENT PUBLICATION TRENDS IN ECLINICAL SOLUTIONS MARKET, 2015–2024 76
FIGURE 26 PATENT ANALYSIS, JANUARY 2015–JUNE 2024 77
FIGURE 27 INDICATIVE PRICING ANALYSIS FOR FIRST YEAR, BY DEPLOYMENT MODEL 83
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TOP 3 END USERS 87
FIGURE 29 KEY BUYING CRITERIA FOR TOP 3 END USERS 88
FIGURE 30 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 89
FIGURE 31 INVESTMENT AND FUNDING SCENARIO 92
FIGURE 32 MARKET POTENTIAL OF AI/GENERATIVE AI ON ECLINICAL SOLUTIONS 93
FIGURE 33 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 95
FIGURE 34 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SNAPSHOT 147
FIGURE 35 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY, 2021 VS. 2022 151
FIGURE 36 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET SNAPSHOT 181
FIGURE 37 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ECLINICAL
SOLUTIONS MARKET 221
FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS IN ECLINICAL SOLUTIONS MARKET,
2019–2023 (USD BILLION) 222
FIGURE 39 ECLINICAL SOLUTIONS MARKET SHARE ANALYSIS, 2023 223
FIGURE 40 RANKING OF KEY PLAYERS IN ECLINICAL SOLUTIONS MARKET, 2023 225
FIGURE 41 ECLINICAL SOLUTIONS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 227
FIGURE 42 ECLINICAL SOLUTIONS MARKET: COMPANY FOOTPRINT 228
FIGURE 43 ECLINICAL SOLUTIONS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 234
FIGURE 44 EV/EBITDA OF KEY VENDORS 237
FIGURE 45 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF COMPUTER VISION SOLUTION VENDORS 237
FIGURE 46 ECLINICAL SOLUTIONS MARKET: BRAND/PRODUCT COMPARISON 238
FIGURE 47 MEDIDATA (A DASSAULT SYSTÈMES COMPANY): COMPANY SNAPSHOT (2023) 243
FIGURE 48 VEEVA SYSTEMS: COMPANY SNAPSHOT (2023) 247
FIGURE 49 IQVIA INC.: COMPANY SNAPSHOT (2023) 252
FIGURE 50 ICON PLC: COMPANY SNAPSHOT (2023) 255
FIGURE 51 ORACLE: COMPANY SNAPSHOT (2023) 258
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11